Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nithya Ramnath

Showing results (61-70 of 142) with videos related to

Pageof 15
Sort By:
Journal for Immunotherapy of Cancer|June 23, 2026
Heterogeneous survival impact of immune-related adverse events in US veteransSadiq Rehmani, Luke Michael Higgins, Daria Brinzevich, et al.
Lung Cancer (Amsterdam, Netherlands)|December 13, 2021
Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancerAlex K Bryant, Kamya Sankar, Garth W Strohbehn, et al.
Journal for Immunotherapy of Cancer|July 29, 2021
It's not 'just a tube of blood': principles of protocol development, sample collection, staffing and budget considerations for blood-based biomarkers in immunotherapy studiesCindy Y Jiang, Zeqi Niu, Michael D Green, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic targetJoo-Heon Kim, Paul N Bogner, Sun-Hee Baek, et al.
Lung Cancer (Amsterdam, Netherlands)|June 7, 2005
Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC)Xiang Ling, Jie Yang, Dongfeng Tan, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2022
De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancerAlex K Bryant, Kamya Sankar, Lili Zhao, et al.
Anti-Cancer Drugs|July 3, 2008
Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II studyNithya Ramnath, Jihnhee Yu, Nikhil I Khushalani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2014
A MicroRNA cluster at 14q32 drives aggressive lung adenocarcinomaErnest Nadal, Jinjie Zhong, Jules Lin, et al.
Cancers|February 15, 2022
Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung CancerKamya Sankar, Alex K Bryant, Garth W Strohbehn, et al.
Small (Weinheim an Der Bergstrasse, Germany)|July 31, 2014
A radial flow microfluidic device for ultra-high-throughput affinity-based isolation of circulating tumor cellsVasudha Murlidhar, Mina Zeinali, Svetlana Grabauskiene, et al.
Pageof 15

Showing results (61-70 of 142) with videos related to

Sort By:
Pageof 15
Journal for Immunotherapy of Cancer|June 23, 2026
Heterogeneous survival impact of immune-related adverse events in US veteransSadiq Rehmani, Luke Michael Higgins, Daria Brinzevich, et al.
Lung Cancer (Amsterdam, Netherlands)|December 13, 2021
Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancerAlex K Bryant, Kamya Sankar, Garth W Strohbehn, et al.
Journal for Immunotherapy of Cancer|July 29, 2021
It's not 'just a tube of blood': principles of protocol development, sample collection, staffing and budget considerations for blood-based biomarkers in immunotherapy studiesCindy Y Jiang, Zeqi Niu, Michael D Green, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic targetJoo-Heon Kim, Paul N Bogner, Sun-Hee Baek, et al.
Lung Cancer (Amsterdam, Netherlands)|June 7, 2005
Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC)Xiang Ling, Jie Yang, Dongfeng Tan, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2022
De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancerAlex K Bryant, Kamya Sankar, Lili Zhao, et al.
Anti-Cancer Drugs|July 3, 2008
Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II studyNithya Ramnath, Jihnhee Yu, Nikhil I Khushalani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2014
A MicroRNA cluster at 14q32 drives aggressive lung adenocarcinomaErnest Nadal, Jinjie Zhong, Jules Lin, et al.
Cancers|February 15, 2022
Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung CancerKamya Sankar, Alex K Bryant, Garth W Strohbehn, et al.
Small (Weinheim an Der Bergstrasse, Germany)|July 31, 2014
A radial flow microfluidic device for ultra-high-throughput affinity-based isolation of circulating tumor cellsVasudha Murlidhar, Mina Zeinali, Svetlana Grabauskiene, et al.
Pageof 15